Roivant Sciences shares gain after ulcerative colitis treatment shows longer-term results
Shares of Roivant Sciences Ltd. (ROIV) gained 14% in premarket trading Thursday after the company released new long-duration data from a study of its monoclonal antibody RVT-3101 in adults with ulcerative colitis. The treatment resulted in improved clinical remission of 36% at week 56, versus 29% at week 14, the company said in a release. Ulcerative colitis is an inflammatory bowel disease that can damage the gastrointestinal tract. The study results suggest that the antibody "has the potential to transform the treatment paradigm for IBD--currently marked by low remission rates and poor persistence of effect," Roivant CEO Matt Gline said in a statement. Roivant late last year teamed up with Pfizer (PFE) to form a new company to develop and commercialize the RVT-3101 antibody. Pfizer shares were down 0.3% premarket on Thursday.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
06-22-23 0809ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Best- and Worst-Performing Stocks of May 2024
-
3 Stocks to Buy and 3 Stocks to Sell in June
-
Markets Brief: Friday’s Job Report in Focus
-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
The Best Utilities Stocks to Buy
-
3 Cheap Dividend Stocks to Buy Yielding 4% or More
-
After Earnings, Is Salesforce Stock a Buy, Sell, or Fairly Valued?
-
Broadcom: Raising Valuation Estimate as AI Becomes a Greater Driver of Growth
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75